Synthetic lethality is a strategy for killing cancer cells by exploiting genetic weaknesses they already carry, rather than blasting every dividing cell in the body. The idea is straightforward: cancer cells often lose the function of protective genes during their development, and those losses create dependencies on backup systems. Block the backup, and the cancer cell dies while healthy cells, which still have both systems intact, survive. This approach has already produced a class of successful drugs and is now branching into areas of cancer biology that were previously considered untreatable.
The Core Logic
Two genes are “synthetic lethal” when losing either one alone is survivable, but losing both at the same time is fatal to the cell. Cancer cells frequently arrive at the clinic with one of those genes already knocked out by mutation. That pre-existing loss becomes a target: if you can pharmacologically disable the partner gene, you selectively kill the tumor and spare normal tissue. The concept provides a way to go after targets that traditional drug design has struggled with, including the loss-of-function mutations in tumor suppressor genes that help drive many cancers in the first place.1PubMed Central. Synthetic Lethality in Cancer Therapeutics: The Next Generation
The PARP and BRCA Story
The clearest success story involves PARP inhibitors and BRCA-mutant cancers. BRCA1 and BRCA2 are genes that help repair serious DNA damage through a process called homologous recombination. Tumors in patients who carry mutations in either BRCA gene have lost that repair pathway.2PubMed Central. PARP inhibitors: Synthetic lethality in the clinic PARP is an enzyme involved in a different, more routine form of DNA repair. When a PARP inhibitor blocks that enzyme in a BRCA-mutant cancer cell, the cell has no functioning repair system left for certain types of DNA damage. It accumulates lethal levels of broken DNA and dies.
The mechanism turns out to be more nuanced than simply “block one repair, lose the other.” PARP inhibitors don’t just prevent PARP from doing its job; they physically trap the PARP protein onto damaged DNA, creating obstacles that stall the machinery cells use to copy their genomes.3PubMed Central. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings Those stalled replication forks need BRCA-dependent repair to be resolved. Without it, they collapse. Different PARP inhibitors trap PARP with different potencies, and that trapping ability doesn’t neatly correlate with how well each drug blocks PARP’s enzymatic activity.4PubMed Central. Differential trapping of PARP1 and PARP2 by clinical PARP inhibitors This distinction matters clinically because drugs that are better trappers tend to be more potent against tumors but can also carry different side-effect profiles.
More recent work has added another layer: replication gaps. When BRCA-deficient cells encounter a PARP inhibitor, they accumulate stretches of exposed single-stranded DNA during replication. These gaps exhaust the cell’s protective proteins and become a critical driver of cell death.5Molecular Cell. Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency Understanding these gaps is reshaping how researchers think about predicting which patients will respond and why some stop responding.
Why Tumors Stop Responding
Resistance to PARP inhibitors is a real and growing clinical problem. The most common route is that the tumor finds a way to restore the homologous recombination repair it originally lost. This can happen through several mechanisms: reversion mutations that fix the broken BRCA gene, changes in how DNA is packaged that reactivate silenced repair genes, or alterations in how the cell protects stalled replication forks.6PubMed Central. PARP inhibitor resistance: the underlying mechanisms and clinical implications
A study of patients with metastatic prostate cancer treated with PARP inhibitors found reversion mutations in roughly four out of five BRCA2/PALB2-mutant tumors by the end of treatment. Many of these reversions were generated by a specific error-prone DNA repair enzyme, and the number and timing of reversions correlated with how long patients stayed progression-free.7PubMed Central. Elucidating acquired PARP inhibitor resistance in advanced prostate cancer Tumors, in other words, are under intense selective pressure to undo the very vulnerability that made them susceptible. This finding has pushed researchers toward combination strategies that might forestall resistance or attack it from multiple angles simultaneously.
Expanding Beyond BRCA With Checkpoint Inhibitors
PARP inhibitors work best in tumors with pre-existing DNA repair defects, but researchers are now engineering that vulnerability in tumors that don’t have it naturally. Several drugs targeting cell-cycle checkpoint kinases, specifically ATR, CHK1, and Wee1, can force otherwise repair-proficient cancer cells into a state that mimics BRCA deficiency. When these checkpoint inhibitors are combined with PARP inhibitors, cells that would normally shrug off PARP inhibition become sensitive to it.8British Journal of Cancer. ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors The concept is sometimes called “induced synthetic lethality,” and it could significantly expand the number of patients who benefit from PARP-based therapy.
Combining ATR and Wee1 inhibitors on their own, without PARP drugs, is another active area. In a preclinical breast cancer model, this combination produced tumor-selective cell killing and led to tumor shrinkage with minimal damage to healthy tissue.9PubMed Central. Inhibiting Wee1 and ATR kinases produces tumor-selective synthetic lethality and suppresses metastasis The selectivity comes from a feature many cancers share: they carry so much DNA damage from their oncogenes that they are already stressed. Healthy cells, which are not carrying that burden, tolerate checkpoint inhibition much better.
Newer work has explored combining ATR inhibition with inhibition of another checkpoint kinase, PKMYT1, in breast cancers that have lost the Rb1 tumor suppressor. By disrupting two different cell-cycle checkpoints at once, this combination forces cancer cells into premature division with unresolved DNA damage, which is lethal.10PubMed. Rb1 deficiency induces synthetic lethality with ATR and PKMYT1 coinhibition in breast cancer cell lines and patient-derived xenografts Single-agent checkpoint inhibitors have often disappointed in clinical trials because cancer cells can compensate through backup pathways. Hitting two checkpoints at once may be what it takes to close those escape routes.
Collateral Damage as Opportunity
One clever variation on synthetic lethality takes advantage of “collateral” gene losses. When a tumor deletes a tumor suppressor gene, nearby genes on the same stretch of chromosome often get deleted too, simply because they are neighbors. These bystander deletions can create targetable vulnerabilities that have nothing to do with the original tumor suppressor.
The best-studied example involves MTAP, a metabolic gene that sits right next to CDKN2A (also known as p16), one of the most commonly deleted tumor suppressors in cancer. When tumors delete CDKN2A, they almost always lose MTAP along with it. Losing MTAP causes a metabolite called MTA to build up inside the cell, and that buildup partially hobbles an enzyme called PRMT5. The cancer cell can still function with reduced PRMT5 activity, but it is living on a thin margin. Inhibit PRMT5 further with a drug, and the cell crosses the lethal threshold.11PubMed. Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5 Two independent research groups identified this vulnerability around the same time, one through genetic screening and the other through metabolic analysis, lending considerable confidence to the finding.12PubMed. MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis PRMT5 inhibitors designed to exploit this interaction are now in clinical trials.
Going After “Undruggable” Oncogenes
Some of the most important cancer-driving genes, such as MYC and KRAS, have long been considered undruggable because their protein products lack the kinds of pockets where small-molecule drugs can easily bind. Synthetic lethality offers a workaround: instead of targeting the oncogene directly, find the genes that the cancer has become dependent on because of the oncogene, and target those instead.
MYC-driven cancers, for example, depend on specific regulators of MYC’s activity and stability. Two components of MYC’s transcription machinery, BRD4 and CDK9, have been identified as synthetic lethal partners, along with proteins that control how quickly MYC is degraded, including PLK1, Pim-1, and aurora kinases. Inhibiting any of these in MYC-driven cancer models suppressed tumor growth. Not every cell-cycle regulator matters equally, though. CDK4/6, despite being regulated by MYC, did not show synthetic lethality, suggesting that MYC-driven tumors are selectively dependent on specific partners rather than broadly vulnerable.13Trends in Pharmacological Sciences. Synthetic Lethality: New Horizons in Cancer Treatment – Section: Mechanisms of MYC Synthetic Lethality in Cancer
KRAS mutations are found in a large fraction of lung, colorectal, and pancreatic cancers. While direct KRAS inhibitors have recently entered the clinic for certain mutations, many KRAS-driven tumors remain difficult to treat. Synthetic lethal approaches target the compensatory pathways KRAS-mutant cells rely on to manage the stress their own oncogene creates.14PubMed Central. Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers Recent work identified a promising combination: simultaneously blocking two signaling proteins, SHP2 and XIAP, induced synthetic lethality in KRAS-mutant lung cancer cells and animal models.15PubMed Central. Synthetic Lethality of SHP2 and XIAP Suppresses Proliferation and Metastasis in KRAS-mutant Nonsmall Cell Lung Cancer
Paralogs and Chromatin Remodelers
Paralogs are pairs or families of genes that arose from gene duplication during evolution. They often perform similar enough functions that losing one is tolerable because the other picks up the slack. But if a cancer cell has already lost one paralog, it becomes critically dependent on the surviving one. Knock out the survivor, and the cell dies, while healthy cells that still have both copies are unaffected.16PubMed Central. Paralog-based synthetic lethality: rationales and applications Large-scale genetic screens across hundreds of cancer cell lines have confirmed that paralog pairs show synthetic lethal interactions at rates higher than non-paralog gene pairs.17Cell Reports. Paralog Genetic Interaction Mapping in Mammalian Cells
A concrete example involves SMARCA2 and SMARCA4, two paralogs that serve as the catalytic engine of an important chromatin-remodeling complex. About one in ten non-small cell lung cancers carry SMARCA4 mutations that knock out its protein. Those tumors become highly dependent on SMARCA2 to keep the chromatin remodeling machinery running. A first-in-human degrader drug, PRT3789, has been designed to selectively destroy the SMARCA2 protein in these tumors.18PubMed. PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers Rather than simply inhibiting SMARCA2’s activity, this drug tags it for destruction by the cell’s own protein-disposal system, a technique known as targeted protein degradation. PROTACs and similar degrader molecules are especially appealing for synthetic lethality because many of the partner proteins researchers want to eliminate are difficult to block with conventional small molecules but can be efficiently degraded.19Molecular Cancer Therapeutics. PROTACs: Current and Future Potential as a Precision Medicine Strategy to Combat Cancer – Section: Expanding the Potential of PROTACs in Cancer Treatment
Finding New Synthetic Lethal Pairs
Discovering which gene pairs are synthetic lethal has shifted from slow, gene-by-gene experiments to industrial-scale screening. CRISPR-based genetic screens are now the dominant tool: researchers systematically knock out every protein-coding gene across hundreds of cancer cell lines and cross-reference the results with the molecular profiles of those cells to find dependencies tied to specific mutations.20Trends in Cancer. Synthetic Lethality: New Horizons in Cancer Treatment – Section: Experimental approaches to identify new synthetic lethal paralog pairs These efforts have generated enormous datasets of genetic vulnerabilities.21PubMed Central. CRISPR Screens in Synthetic Lethality and Combinatorial Therapies for Cancer
Computational methods are catching up fast. One framework, called SLAYER, integrates cancer genomic data with genome-wide CRISPR knockout results across over a thousand cancer cell lines to predict synthetic lethal pairs by examining both direct mutation-dependency relationships and pathway-level connections.22NAR Genomics and Bioinformatics. SLAYER: a computational framework for identifying synthetic lethal interactions through integrated analysis of cancer dependencies Machine learning approaches are also being applied, though a recent benchmarking study of twelve different methods revealed that the quality of the training data matters as much as the algorithm. All methods performed substantially better when computationally derived synthetic lethal pairs were excluded from training and when negative labels were chosen based on gene-expression data.23Nature Communications. Benchmarking machine learning methods for synthetic lethality prediction in cancer The field is generating predictions faster than they can be validated in the lab, which creates both opportunity and a risk of false leads.
Picking the Right Patients
Having a synthetic lethal drug is only useful if you can reliably identify the patients whose tumors carry the corresponding vulnerability. For PARP inhibitors, the first-generation approach was simple: test for BRCA1/2 mutations. But researchers quickly realized that many tumors without BRCA mutations also have defective homologous recombination repair, a state broadly called HRD, and these patients might benefit too. The challenge is developing tests that reliably detect HRD beyond just BRCA status.24PubMed. Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors
A real-world study in ovarian cancer compared outcomes using a genomic “scar” signature for HRD against standard BRCA testing alone. Patients whose tumors tested positive for the HRD signature and received PARP inhibitor maintenance therapy had substantially better progression-free survival compared to those who did not receive maintenance, regardless of BRCA status. Patients who were BRCA-wild-type but HRD-signature-positive still showed a meaningful benefit from PARP inhibitors, while patients who were negative on the HRD signature showed no benefit at all.25PubMed Central. Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice This kind of biomarker refinement is essential. Without it, patients receive drugs that won’t help them and may cause unnecessary side effects, while patients who would benefit get overlooked.
Synthetic Lethality Meets Immunotherapy
One of the more unexpected developments is the discovery that synthetic lethal drugs can prime the immune system to attack tumors. When cancer cells die from DNA damage, they sometimes release fragments of DNA into their own cytoplasm, triggering an immune-sensing pathway called cGAS-STING. This pathway signals the presence of danger and recruits immune cells, particularly CD8+ T cells, to the tumor. PARP inhibitors have been shown to depend on this immune recruitment to achieve their full anti-tumor effect.26Science Translational Medicine. PARP inhibitors need an extra STING for therapeutic efficacy
Inhibitors of polymerase theta, another DNA repair enzyme, appear to activate this same cGAS-STING pathway in repair-deficient cancers, boosting the production of immune-signaling molecules and increasing the infiltration of T cells into tumors.27Nature Communications. Polymerase θ inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in models of BRCA-deficient cancer These findings have spurred clinical trials combining synthetic lethal drugs with immune checkpoint inhibitors, on the logic that DNA-damage-based treatments can make tumors “hotter” for the immune system while checkpoint inhibitors remove the brakes on T cells. How well this translates to patient outcomes is still being worked out, but the biological rationale is strong enough to have attracted major investment.
Variations on the Theme
The classic definition of synthetic lethality involves two loss-of-function events. But related concepts are expanding the playbook. Synthetic dosage lethality describes a situation where overexpression of one gene combined with the loss of another is lethal.28PubMed Central. Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation This is particularly relevant for cancers driven by overactive oncogenes, which are often hard to drug directly. Rather than trying to shut down the oncogene, you inhibit a gene whose loss becomes fatal specifically because the oncogene is cranked up. A systematic study found that synthetic dosage lethal interactions predicted from metabolic network modeling correlated with tumor growth rates and patient survival, suggesting these interactions are clinically relevant and not just theoretical.29PubMed Central. Synthetic dosage lethality in the human metabolic network is highly predictive of tumor growth and cancer patient survival
Contextual synthetic lethality pushes the concept even further, beyond the tumor cell itself and into its surrounding environment. Tumors do not exist in isolation; they grow within a microenvironment of blood vessels, immune cells, and connective tissue, and that microenvironment actively shapes how the tumor evolves and responds to treatment. Researchers have proposed that synthetic lethal thinking should encompass vulnerabilities created by the interaction between tumor cells and their surroundings, not just vulnerabilities within the tumor’s own genome.30PubMed Central. Leveraging microenvironmental synthetic lethalities to treat cancer A tumor that depends on a particular immune-suppressive signal from its microenvironment, for instance, might be killable by disrupting that signal in combination with a targeted therapy, even if neither intervention works alone.
Where the Gaps Still Are
For all its promise, translating synthetic lethality from laboratory screens to effective treatments remains difficult. Many gene pairs that look lethally connected in cell lines fail to hold up in animal models, let alone in patients. Part of the problem is that cancer cells in a dish behave differently than cancer cells living inside a person, surrounded by immune cells, blood supply, and varying oxygen levels. Another part is that tumors are not genetically uniform; different cells within the same tumor may carry different mutations, which means a synthetic lethal drug might kill most of the tumor while leaving resistant subclones untouched.
The sheer number of potential synthetic lethal pairs is both exciting and daunting. Computational tools can now propose thousands of candidate interactions, but experimental validation is slow and expensive. There is a real risk that the field gets buried in false positives if the quality bar for training data and validation is not kept high. The benchmarking of machine learning methods has made clear that methodological choices like how negative examples are selected can dramatically change which pairs a model predicts as synthetic lethal.23Nature Communications. Benchmarking machine learning methods for synthetic lethality prediction in cancer Getting the informatics right is not a footnote to the biology; it is a prerequisite for productive drug development in this space.